Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria

NCT02613208 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02613208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
December 9, 2015
Completion date
December 3, 2018
Enrollment
111 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer